The rise of DOLs doesn’t mean pharma should upend KOL approach.
Read Roberts
Advertisement
Director, KOL Data Solutions, PRECISIONscientia
Articles by Read Roberts
Advertisement
Latest Updated Articles
Food for Thought: Make Room for Multiple OpinionsMarch 10th 2023
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5